ImmuCell Corporation (ICCC) Insider Trading

Last 12 months

Insiders bought $123k on the open market and sold nothing.

Net open-market

+$123k

3 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

2 / 0

executives and directors

Last open-market buy

Jun 2026

Jun 18, 2026

Get an email when ICCC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 18	Boekhorst Paul Francis Olivier Te President and CEO	Bought	8,000	$9.50	$76k	82%	Form 4
Dec 3, 2025 – Dec 4, 2025	Boekhorst Paul Francis Olivier Te President and CEO	Bought 2 parts	6,030	$5.23 average	$32k	163%	Form 4
Nov 25, 2025	David Scott Tomsche Director	Bought 2 parts	3,266	$4.77 average	$16k	2.5%	Form 4
Jun 12, 2025	Bryan K. Gathagan Director	Bought	1,000	$6.32	$6k	New	Form 4

Jun 18
Boekhorst Paul Francis Olivier Te
President and CEO · bought 8,000 at $9.50
$76k
82% of stake
Dec 3, 2025 – Dec 4, 2025
Boekhorst Paul Francis Olivier Te
President and CEO · bought 6,030 at avg $5.23
$32k
163% of stake
Nov 25, 2025
David Scott Tomsche
Director · bought 3,266 at avg $4.77
$16k
2.5% of stake
Jun 12, 2025
Bryan K. Gathagan
Director · bought 1,000 at $6.32
$6k
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ICCC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: In Vitro & In Vivo Diagnostic Substances

TKNOAlpha Teknova, Inc.

BMRABiomerica Inc.

NTLAIntellia Therapeutics Inc.

SCLXScilex Holding Company

VSTMVerastem Inc.

VRCAVerrica Pharmaceuticals Inc.

CWLXFC21 Investments Inc.

CPIXCumberland Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in ICCC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ICCC

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.